Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer, Radiation Toxicity

In brief

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.

Key facts

Study ID

NCT00003307

Run by

University of Arizona

People needed

25

Starts

1998-03-01

Expected to finish

2001-06-01

Last updated by the study team

2010-03-16

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.